NME6

Across TCGA pan-cancer cohorts, NME6 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NME6 data layer compared with 25 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher NME6 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated NME6 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

PDAC, HNSC, and LSCC are the cancer types where NME6 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.672	0.981	.001	37	view →
HNSC	OS	Median	II,III,IV	1.000	0.938	.022	7	view →
LSCC	OS	Median	III,IV	0.547	0.905	.020	3	view →
CCRCC	OS	Quartile	All	1.000	0.568	.049	2	view →
GBM	DFS	Quartile	All	0.603	0.781	.029	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NME6–PDAC (OS)

Open the PDAC breakdown →